Potassium ions in gastrointestinal lumen (K+)

Potassium ions in the gastrointestinal lumen are a therapeutic target for treating hyperkalemia, particularly in patients with chronic kidney disease (CKD) or heart failure (HF) [PMID: 31434554]. Under normal physiological conditions, the kidneys are responsible for approximately 90% of potassium excretion, while the gut handles the remaining 10%; however, in the presence of renal failure, the gut's role in potassium disposal significantly increases [PMID: 27026518]. Drugs targeting these ions, known as potassium binders, work by sequestering K+ within the GI tract to prevent systemic absorption and enhance fecal elimination [StatPearls: Hyperkalemia]. These agents include sodium polystyrene sulfonate (SPS), patiromer, and sodium zirconium cyclosilicate (SZC), which utilize cation exchange mechanisms to swap ions like sodium, calcium, or hydrogen for potassium [PMID: 30859914]. By reducing the total body potassium burden through the intestinal route, these therapies help prevent life-threatening cardiac arrhythmias associated with high serum potassium levels [PMID: 29761351].

Other names

Luminal potassiumGastrointestinal potassiumK+ ionsIntestinal potassium

The mechanism involves cation exchange where the therapeutic agent (a non-absorbed polymer or inorganic crystal) releases a counter-ion, such as sodium, calcium, or hydrogen, in exchange for binding luminal potassium ions [PMID: 25495244, PMID: 26393484]. This binding occurs primarily in the colon for patiromer or throughout the entire gastrointestinal tract for sodium zirconium cyclosilicate, leading to increased fecal potassium excretion and a subsequent reduction in systemic serum potassium concentration [PMID: 31434554].